Mallinckrodt Revenue and Competitors
Estimated Revenue & Valuation
- Mallinckrodt's estimated annual revenue is currently $1.1B per year.
- Mallinckrodt's estimated revenue per employee is $336,352
- Mallinckrodt's total funding is $97M.
Employee Data
- Mallinckrodt has 3270 Employees.
- Mallinckrodt grew their employee count by 0% last year.
Mallinckrodt Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $44.2M | 201 | 5% | N/A | N/A |
What Is Mallinckrodt?
Tyco Healthcare/Mallinckrodt, based in St. Louis, Missouri, manufactures and markets medical products. Our mission is to improve healthcare for patients worldwide by providing superior products that sustain breathing, diagnose disease and relieve pain. We are committed to producing products that bring better healthcare to patients, more value to medical professionals, greater opportunity to employees, and increased earnings to reward Tyco shareholders.
keywords:N/A
$97M
Total Funding
3270
Number of Employees
$1.1B
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Mallinckrodt's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Director, Enterprise Applications | Reveal Email/Phone |
2 | Executive Director Clinical Operations | Reveal Email/Phone |
3 | EVP and Chief Human Resources Officer | Reveal Email/Phone |
4 | Sr. Director, Business Development and Licensing | Reveal Email/Phone |
5 | VP Medical Devices | Reveal Email/Phone |
6 | Director Compliance - Hospital Business | Reveal Email/Phone |
7 | Assistant Treasurer | Reveal Email/Phone |
8 | Senior Director Marketing and Brand Lead | Reveal Email/Phone |
9 | Director, Regional Accounts, Autoimmune & Rare Diseases Business | Reveal Email/Phone |
10 | Senior Rare Disease Sales Specialist/ Trainer | Reveal Email/Phone |
Mallinckrodt News
Postoperative Pain Therapeutics Market Growth and Demands ... Digital Journal
Mallinckrodt Announces Publication of Real-World Data from ... PR Newswire
Silence Therapeutics and Mallinckrodt Announce Submission of ... BioSpace